Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

Inhalon's headquarters in Durham, NC, United States

John Whelan

Bill Picht

Thomas Moench

Sam Lai

Seth Hetherington

Richard Fuller

Winnie H Wan

The Scientific Team at Inhalon Biopharma is responsible for researching, designing, and developing the inhaled immunotherapy platform aimed at treating a range of acute respiratory infections (ARIs). Team members, including Associate Scientists, Senior Scientists, and QA/QC specialists, collaborate to conduct experiments, analyze data, and ensure the efficacy and safety of potential treatments, ultimately advancing therapeutic solutions for ARIs like RSV, influenza, and SARS.

Scientific Team

The Leadership Team at Inhalon Biopharma is responsible for steering the company's strategic vision and operational direction, driving the development of innovative inhaled immunotherapy solutions for acute respiratory infections. Comprising key executives and founders, this team collaborates to oversee clinical trial designs, regulatory compliance, and partnerships, ensuring the successful advancement of groundbreaking therapies from research to market while addressing critical unmet medical needs.

Inhalon

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Offices

Inhalon

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Offices

Related companies